Immuneering Balance Sheet Health
Financial Health criteria checks 5/6
Immuneering has a total shareholder equity of $66.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $77.1M and $10.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$59.73m |
| Equity | US$66.31m |
| Total liabilities | US$10.78m |
| Total assets | US$77.09m |
Recent financial health updates
Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky
Aug 30
Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
May 13Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
Jan 06We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate
Aug 17Recent updates
Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky
Aug 30Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
May 13Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
Mar 19Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
Jan 06We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate
Aug 17Immuneering wins FDA nod to study lead asset in solid tumors
Sep 30Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate
Sep 02Immuneering initiated a Buy by Chardan, PT set to $18
Jul 08Financial Position Analysis
Short Term Liabilities: IMRX's short term assets ($63.7M) exceed its short term liabilities ($6.8M).
Long Term Liabilities: IMRX's short term assets ($63.7M) exceed its long term liabilities ($4.0M).
Debt to Equity History and Analysis
Debt Level: IMRX is debt free.
Reducing Debt: IMRX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IMRX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 30.9% each year